...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of gastroenterology and hepatology >Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
【24h】

Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.

机译：替加色罗对便秘为主的肠易激综合症男性患者结肠转运时间的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND AND AIMS: Tegaserod is approved for the treatment of constipation-predominant irritable bowel syndrome (C-IBS) in females. The aim of this study was to evaluate the effect of tegaserod on colonic transit time (CTT) and symptoms in male patients with C-IBS. METHODS: Forty-four males with C-IBS (Rome II) were enrolled. After a baseline washout period of 2 weeks, 40 patients were randomized to 6 mg twice daily of tegaserod or placebo for 12 weeks. Daily bowel habits and weekly satisfactory relief of symptoms were recorded. Total and segmental CTT were measured using radiopaque markers at baseline and after treatment. RESULTS: The mean +/- SD for the total colonic, right colonic, left colonic and rectosigmoid transit time (in hours) were 18.96 +/- 3.92, 7.74 +/- 1.55, 5.64 +/- 1.51 and 5.58 +/- 2.2 in the tegaserod group compared to 22.47 +/- 3.73, 9.69 +/- 2.33, 6.6 +/- 1.32 and 6.18 +/- 2.22 in the placebo group at the end of 12 weeks. There was a statistically significant difference in the total, right and left CTT in the tegaserod group (P < 0.05) at the end of treatment. Global satisfactory relief at the end of 12 weeks was 75% in the tegaserod group and 50% in the placebo group (P > 0.05). Greater stool frequency occurred in the tegaserod group (P > 0.05). There was a significant decrease in the stool consistency at the end of 12 weeks in patients treated with tegaserod (P < 0.05). CONCLUSIONS: Tegaserod causes significant acceleration of CTT in male patients with C-IBS. Although there was a trend towards improvement in bowel symptoms in the treated group, this effect was not statistically significant.
机译：背景与目的：Tegaserod被批准用于治疗女性以便秘为主的肠易激综合症（C-IBS）。这项研究的目的是评估替加色罗对男性C-IBS患者结肠转运时间（CTT）和症状的影响。方法：44名男性患有C-IBS（罗马II）。在2周的基线冲洗期后，将40位患者随机分配到替加色罗或安慰剂中，每天两次两次，每次6 mg，共12周。记录每天的排便习惯和每周令人满意的症状缓解。在基线和治疗后使用不透射线标记物测量总CTT和节段CTT。结果：总结肠，右结肠，左结肠和直肠乙状结肠总转移时间的平均+/- SD（小时）分别为18.96 +/- 3.92、7.74 +/- 1.55、5.64 +/- 1.51和5.58 +/- 2.2与安慰剂组在12周结束时相比，替加色罗组中的22.47 +/- 3.73、9.69 +/- 2.33、6.6 +/- 1.32和6.18 +/- 2.22。治疗结束时，替加色罗组的总CTT值，左CTT值和左CTT值存在统计学差异（P <0.05）。替加色罗组在12周末的总体满意缓解率为75％，安慰剂组为50％（P> 0.05）。替加色罗组大便频率更高（P> 0.05）。用替加色罗治疗的患者在12周末的粪便稠度显着降低（P <0.05）。结论：替加色罗可导致男性C-IBS患者的CTT明显加速。尽管在治疗组中肠症状有改善的趋势，但这种作用在统计学上并不显着。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号